Talon Private Wealth LLC Invests $839,000 in Halozyme Therapeutics, Inc. $HALO

Talon Private Wealth LLC bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 10,725 shares of the biopharmaceutical company’s stock, valued at approximately $839,000.

A number of other institutional investors have also recently bought and sold shares of HALO. California State Teachers Retirement System increased its position in Halozyme Therapeutics by 7,724.2% during the second quarter. California State Teachers Retirement System now owns 10,668,044 shares of the biopharmaceutical company’s stock worth $834,988,000 after purchasing an additional 10,531,698 shares during the last quarter. Bank of America Corp DE acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $214,504,000. William Blair Investment Management LLC acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $196,540,000. Norges Bank purchased a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at $128,201,000. Finally, Jupiter Topco LLC purchased a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at $105,570,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on HALO. Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $83.00 to $110.00 in a research report on Friday, August 7th. TD Cowen boosted their price target on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Wells Fargo & Company upped their price target on Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Finally, Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, August 31st. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $91.20.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $104.18, for a total value of $2,083,600.00. Following the completion of the sale, the chief executive officer owned 767,780 shares in the company, valued at approximately $79,987,320.40. This trade represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the firm’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the sale, the director owned 14,462 shares in the company, valued at approximately $1,084,650. The trade was a 33.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 32,478 shares of company stock valued at $3,076,604 over the last quarter. Company insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Stock Up 0.2%

Shares of NASDAQ:HALO traded up $0.20 during midday trading on Friday, hitting $107.20. 861,533 shares of the company’s stock traded hands, compared to its average volume of 1,843,557. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The company has a market cap of $12.17 billion, a PE ratio of 32.00, a P/E/G ratio of 0.42 and a beta of 0.88. The firm’s fifty day moving average price is $93.18 and its two-hundred day moving average price is $76.75. Halozyme Therapeutics, Inc. has a twelve month low of $61.22 and a twelve month high of $111.15.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The firm had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. During the same period in the prior year, the firm earned $1.54 EPS. The firm’s quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 7.98 EPS for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.